Each ml. of Oxsoralen Lotion contains 10 mg methoxsalen in an inert vehicle containing alcohol (71% v/v), propylene glycol, acetone, and purified water.
As a topical repigmenting agent in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight.
Media Articles Related to Oxsoralen Topical (Methoxsalen Topical)
Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Source: MedicineNet Vitiligo Specialty [2015.06.25]
Title: Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM
Vitiligo: A Common Cause of Loss of Skin Pigment
Source: MedicineNet Vitiligo Specialty [2014.12.01]
Title: Vitiligo: A Common Cause of Loss of Skin Pigment
Category: Doctor's Views
Created: 6/2/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM
Source: MedicineNet Achalasia Specialty [2014.11.01]
Category: Diseases and Conditions
Created: 7/11/1999 12:00:00 AM
Last Editorial Review: 11/1/2014 12:00:00 AM
Published Studies Related to Oxsoralen Topical (Methoxsalen Topical)
An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. [2003.07]
We compared the characteristics of psoralen and ultraviolet A (PUVA) erythema in skin photosensitized by bath or oral methoxsalen in 20 subjects. Erythema was assessed visually and with a reflectance instrument at 24 h intervals for 7 days.
The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion. [2003.03]
CONCLUSIONS: Methoxsalen-UV-A erythema exhibited a broad plateau between 96 and 144 hours, with most subjects at peak erythema at 120 hours. Reduction of methoxsalen immersion time significantly lowered the erythemal intensity. Minimum phototoxic dose reading at 72 hours underestimates the phototoxic effect of topical methoxsalen PUVA, and a change in the MPD assessment time should be considered.
Microemulsions for topical delivery of 8-methoxsalen. [2000.10.03]
8-Methoxsalen (8-MOP) and related furocumarins have been extensively used for the treatment of hyperproliferative skin diseases in association with long-wavelength UVA light. In order to develop alternative formulations for the topical administration of 8-MOP, microemulsions were evaluated as delivery vehicles...
Clinical Trials Related to Oxsoralen Topical (Methoxsalen Topical)
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease [Completed]
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a
clinical response (i. e., a CDAI decrease greater than or equal to 100 from baseline and/or a
CDAI < 150) over a 12-week period in moderately active Crohn's disease (CDAI greater than or
equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants
and/or anti-TNF agents. This study will also assess response to continued treatment during
a 12-week Extension Period in patients who have a clinical response at Week 12 of the
Treatment Period and elect to participate in the Extension Period.
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Active, not recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal
photopheresis therapy when added to standard drug therapies administered to patients with
moderate to severe chronic graft-versus-host disease.
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease [Terminated]
The purpose of this study is to compare the safety and efficacy of ECP treatment combined
with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of
patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days
following an allo HPCT.
UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease [Not yet recruiting]
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen)
Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems in pediatric
patients with steroid-refractory aGvHD. The study is composed of Screening, Treatment, and
PUVA Maintenance Therapy in Mycosis Fungoides [Recruiting]
The purpose of the study is to determine whether psoralen plus UVA (PUVA) photochemotherapy
maintenance treatment prolongs disease-free survival of cutaneous T cell lymphoma (mycosis